ACP Comments on CMS’ CY23 Medicare Advantage (Part C) and Medicare Prescription Drug Benefit (Part D) Programs Proposed Rule

ACP comment letter on the CMS proposed rulemaking regarding policy and technical changes to the Medicare Advantage (Part C) and Medicare Prescription Drug Benefit (Part D) program regulations for Contract Year 2023.

Brooker

Centers for Medicare and Medicare Services; CMS; Medicare Advantage; MA; Part C program; Medicare Prescription Drug Benefit; Part D program; beneficiary cost sharing adjustments; prescription drugs; Medicare Part D low income subsidy; marketing and communications oversight; plan request denials; Medicare Advantage organizations; MAOs; Star Rating; medical loss ratio; MLR; special needs plans; SNPs; Medicare Medicaid dual eligible; DSNPs; health risk assessments; social drivers of health.

Mon, 03/07/2022 - 4:48 PM EST

Thu, 03/10/2022 - 9:34 AM EST

4

acp_comments_on_cms_cy23_medicare_advantage_and_medicare_prescription_drug_benefit_programs_proposed_rule_march_2022.pdf

{"Author":"Brooker","CreationDate":"2022-03-07T16:48:55-05:00","Creator":"Microsoft\u00ae Word for Microsoft 365","Keywords":"Centers for Medicare and Medicare Services; CMS; Medicare Advantage; MA; Part C program; Medicare Prescription Drug Benefit; Part D program; beneficiary cost sharing adjustments; prescription drugs; Medicare Part D low income subsidy; marketing and communications oversight; plan request denials; Medicare Advantage organizations; MAOs; Star Rating; medical loss ratio; MLR; special needs plans; SNPs; Medicare Medicaid dual eligible; DSNPs; health risk assessments; social drivers of health. ","ModDate":"2022-03-10T09:34:10-05:00","Producer":"Microsoft\u00ae Word for Microsoft 365","Title":"ACP Comments on CMS\u2019 CY23 Medicare Advantage (Part C) and Medicare Prescription Drug Benefit (Part D) Programs Proposed Rule","Pages":4}

2022